Lithium is one of the most widely used drugs in neuropsychopharmacology. Preclinical scientists have made several advances in ascertaining the molecular mechanisms of action of this cation; such as its ability to stabilize monoamine levels, to interact with second messengers, and its neuroprotective effects, possibly over suicidal behaviors. Nevertheless, there remains a gap of knowledge between the pharmacological advances and the number of reliable clinical trials, creating a lack of evidence-based medicine to support medical prescriptions. In this review we examine lithium's molecular mechanisms of action and evaluate their relevance in clinical applications.
Introduction
If we compare the traditional psychiatric drug therapies, lithium is one of the oldest drugs on 
Lithium pharmacodynamics
All human body tissues maintain a sodium electrochemical gradient. This gradient is necessary for a wide variety of transport functions, such as glucose and aminoacids uptake, ion transport, and others. These functions are essential to maintain cell excitability and in controlling intracellular sodium concentrations, cellular pH and intracellular calcium levels [3] .
Before the therapeutic use of lithium, clinicians had observed that changes in serum sodium levels correlated with changes in the mood of bipolar patients. reported high intracellular sodium concentrations during the manic phase and in BD patients [4] .
Later studies demonstrated that lymphoblasts and lymphocytes in these patients had less capacity to respond to ionic stress involving increased levels of intracellular sodium than cells in control individuals [5] . This response may reflect a dysregulation of Na/K-ATPase expression [6] .
Ion-gated channels, which are driven either by adenosine triphosphate (ATP) or the net free energy change, regulate the distribution of lithium across the cell membrane. Conversely, lithium removes sodium in electrically active cells, by replacing a sodium ion [7] . Several studies have evaluated Na/K-ATPase activity in patients with mood disorders. These clinical studies have been limited by their size and often by variable results. However, there is evidence that Na/K-ATPase activity may be reduced in patients with mood disorders, especially during the depressed phase. This decrease is associated with an increase in sodium retention [8] . Long-term lithium treatment has been observed to produce an accumulation of lithium and an increase in Na/K-ATPase activity in erythrocyte membranes with a concomitant reduction of sodium and calcium in the erythrocytes of patients with BD [9] . The high intracellular calcium levels in bipolar patients are further evidence of ion deregulation in BD [10, 11] .
Intracellular calcium levels have returned to
normal values when patients have been treated with lithium [10, 12] , while the consequences of high intracellular sodium and calcium levels are believed to effect the expression of bipolar symptoms [13] . El-Mallakh and Li [14] [19, 20] . Accordingly, lithium blocks the recycling of inositol for the resynthesis of inositol phospholipids and also avoids de novo synthesis from glucose-6-phosphate [7] .
This inhibitory action of lithium on inositol phosphate metabolism has led to the inositol depletion hypothesis of lithium's action, which posits that lithium's therapeutic effects may result from interfering with IP3-mediated cell signaling caused by inositol depletion [19] .
Using this inositol depletion mechanism, lithium has indeed been found to inhibit the collapse of sensory growth cones in cultured sensory neurons and to increase these cone areas [21] . Nevertheless, this hypothesis remains insufficient in providing a complete 
GSK3β
Growing evidence in the literature also indicates that GSK3β is a major regulator of inflammation. Dysfunction of this enzyme has been implicated in the pathophysiology of mood disorders, schizophrenia, Alzheimer's disease (AD), diabetes, cancer, inflammatory and autoimmune diseases [21] . Recent studies have suggested that AD PRESENILIN-1 (PSEN-1) mutations might compromise neuronal function by increasing GSK3β activity and impairing kinesin-based motility [24] .
Interestingly, GSK3β also participates in tauprotein hyperphosphorylation [25] .
As a competitive inhibitor of magnesium, lithium was found to directly inhibit the ATPmagnesium-dependent catalytic activity of GSK3β [26] . In addition, this enzyme inhibition leads to an increase in intracellular β-catenin by decreasing its degradation, and to the consequent activation of the Wnt/β-catenin signaling pathway [27] . 
Adenylyl cyclase and cAMP systems
The adenylyl cyclase system (AC) is an 
HSP70 is induced by ischemia in brain areas
relatively resistant to such insult [38] .
In addition, in a Huntington's disease model using rats, lithium reduces excitotoxin-induced apoptotic death of medium-sized spiny striatal neurons and this effect is associated with Bcl-2 up regulation and caspase-3 downregulation [39, 40] .
Serotonin system
Two classes of serotonin receptors, 5-HT1
and 5-HT2, appear to be involved and play opposite roles in regulating GSK3 activity. 
Clinical implications
As highlighted throughout this review, lithium has many sites of action. This affords it the potential of having many clinical applications, irrespective of its already known uses in bipolar disorder.
Aggression and lithium
In a meta-analysis, Jones and coworkers 
